Global sequencing leader, Illumina, is building up its early talent in its Europe, Middle East and Africa (EMEA) region. Its goal being that early in career talent will eventually make up 20% of its employee population. To kick start the initiative, Illumina is looking to recruiting more than 80 new hires into Early Talent roles across the region in 2022.
Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.
Illumina has welcomed 35 interns to Granta Park, where they will gain unrivalled insight into life at the world’s leading DNA sequencing company. Selected from 4,000 applications for this year’s intake, the students from universities across the UK will take up roles in R&D, product development, commercial and corporate functions, for periods of either 12 weeks or 12 months.
South Cambridgeshire MP Anthony Browne visits Illumina Centre to learn about its ground-breaking science
South Cambridgeshire MP Anthony Browne visited the Illumina Centre to find out more about the ground-breaking science in his constituency. The Conservative MP was given a guided tour of the offices and state-of-the-art Solutions Lab, where he witnessed the powerful technology behind the company’s sequencing success.
Illumina supports Israel's national programme to accelerate diagnoses of critically-ill newborns with suspected genetic disease
Whole-genome sequencing (WGS) enables faster identification of disease-causing genetic abnormalities in infants improving clinical care and management.
llumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator. The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, invested in four companies for the 3rd funding cycle of Illumina Accelerator Cambridge, UK, and three companies for the 13th funding cycle of…
Illumina, Inc. has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the US and UK. The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, invested in four companies for the second funding cycle of Illumina Accelerator Cambridge, UK and five companies for the twelfth funding cycle…
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China, a leading investment firm, have announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Illumina, Inc. and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction.
Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Three companies comprise the inaugural funding cycle of Illumina Accelerator Cambridge, UK, and four companies will join as part of the 11th funding cycle in the San Francisco…
Illumina partners with leading European venture capital firms to build breakthrough genomics startups.
SAN DIEGO--(BUSINESS WIRE)--Apr. 24, 2018-- Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2018.
Bristol-Myers Squibb and Illumina announce strategic collaboration to develop and commercialize companion diagnostics for Bristol-Myers Squibb’s oncology immunotherapies.
Illumina, Inc. has announced estimated first quarter revenue of approximately $572 million, a 6% increase compared to $539 million in the first quarter of 2015 and 7% growth on a constant currency basis. This estimate, which is unaudited, is based on management's preliminary financial analysis.
Illumina, Inc. has announced that it has committed to invest $100M in a new venture capital firm that is strategically aligned with Illumina’s vision to improve human health by unlocking the power of the genome.
Illumina, Inc has announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood.
Life Sciences Minister George Freeman MP attended BioMed Realty’s groundbreaking ceremony of the new 155,000 square foot pre-let laboratory building for Illumina at Granta Park, Cambridge, yesterday (Weds).
(BUSINESS WIRE)--Illumina, Inc. announced it has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of industry-leading laboratory information management systems (LIMS) for life sciences organisations.
Illumina, Inc. has announced the launch of Illumina SeqLab, an integrated solution for customers with HiSeq X™ Systems to enable large-scale human whole-genome sequencing operations.
Annoroad and Illumina, Inc. today announced they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.
Cloud Health will promote the application of genetic sequencing technologies for both public health and clinical research within China, using the most powerful whole-genome sequencing platform in the world.
Berry Genomics NextSeq CN500 instrument and non-invasive prenatal testing reagent kit receives Chinese FDA premarket clearance.
Illumina, Inc. announced it has formed a collaboration with Merck Serono, the biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic.
Illumina, Inc. today announced it has extended its distribution channel through a new relationship with Albiogen Ltd., a life science distributor that specializes in next-generation sequencing (NGS), headquartered in Moscow.